Individualized Prediction for Risk of Recurrence in Stage I/II Melanoma Patients With Negative Sentinel Lymph Node
Shu‐Ching Chang, Kristel Lourdault, Gary L. Grunkemeier, Douglas A. Hanes, Shih‐Ting Chiu, Stacey Stern, Richard Essner · 2024
Read Individualized Prediction for Risk of Recurrence in Stage I/II Melanoma Patients With Negative Sentinel Lymph Node by Shu‐Ching Chang, Kristel Lourdault, Gary L. Grunkemeier, Douglas A. Hanes, Shih‐Ting Chiu, Stacey Stern, Richard Essner (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11605731.txt.
Description
Shu-Ching Chang and co-authors build a personal risk score for melanoma's return in a 2024 study. Early-stage melanoma usually ends well, yet up to thirty percent of patients later develop spread. The team derived a score from five clinical and tissue factors in over twenty-six hundred patients with clear sentinel nodes.
A Gompertz survival model fit the score best, beating standard rivals on fit tests. Its predictions tracked real outcomes closely at two, five, and ten years. Discrimination stayed strong for two decades of follow-up. Ten-year recurrence risk ran from under five percent in the lowest third of scores to about a third in the highest. The authors offer the tool for individualized counseling: a patient can see their own time-shaped risk, not a stage average. They present it as ready for guiding follow-up intensity.
Catalog record
| CREATOR | Shu‐Ching Chang, Kristel Lourdault, Gary L. Grunkemeier, Douglas A. Hanes, Shih‐Ting Chiu, Stacey Stern, Richard Essner |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |